Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation

Huangfei Yu, Hongwei Xia, Qiulin Tang, Huanji Xu, Guoqing Wei, Ying Chen, Xinyu Dai, Qiyong Gong, Feng BiScientific 2017 · DOI

Abstract

Acetylcholine (ACh), known as a neurotransmitter, regulates the functions of numerous fundamental central and peripheral nervous system. Recently, emerging evidences indicate that ACh also plays an important role in tumorigenesis. However, little is known about the role of ACh in gastric cancer. Here, we reported that ACh could be auto-synthesized and released from MKN45 and BGC823 gastric cancer cells. Exogenous ACh promoted cell proliferation in a does-dependent manner. The M3R antagonist 4-DAMP, but not M1R antagonist trihexyphenidyl and M2/4 R antagonist AFDX-116, could reverse the ACh-induced cell proliferation. Moreover, ACh, via M3R, activated the EGFR signaling to induce the phosphorylation of ERK1/2 and AKT, and blocking EGFR pathway by specific inhibitor AG1478 suppressed the ACh induced cell proliferation. Furthermore, the M3R antagonist 4-DAMP and darifenacin could markedly inhibit gastric tumor formation in vivo. 4-DAMP could also significantly enhance the cytotoxic activity of 5-Fu against the MKN45 and BGC823 cells, and induce the expression of apoptosis-related proteins such as Bax and Caspase-3. Together, these findings indicated that the autocrine ACh could act through M3R and the EGFR signaling to promote gastric cancer cells proliferation, targeting M3R or EGFR may provide us a potential therapeutic strategy for gastric cancer treatment.

Introduction

Gastric cancer remains a leading cause of cancer-related mortality worldwide, frequently diagnosed at advanced stages where surgical options are limited. Traditionally characterized as a neurotransmitter, acetylcholine (ACh) is increasingly recognized for its "non-neuronal" roles in various malignancies. This study investigates whether gastric cancer cells autonomously produce ACh and how this molecule influences tumor progression through specific signaling pathways.

Methods

The researchers utilized a multi-disciplinary approach:

  • Cell Lines: Human gastric cancer lines (MKN28, MKN45, BGC823, MGC803, SGC7901) and a normal control (GES-1).
  • Protein Analysis: Western blotting and Immunohistochemistry (IHC) were employed to detect Choline Acetyltransferase (ChAT)—the enzyme responsible for ACh synthesis—and various muscarinic receptors.
  • Quantification: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) measured secreted ACh levels.
  • Pathway Inhibition: Pharmacological antagonists (e.g., 4-DAMP for M3R, AG1478 for EGFR) and siRNA were used to dissect signaling cascades.
  • Proliferation and In Vivo Models: Growth was assessed via CCK-8 and plate clone assays, while xenograft models in nude mice tested the efficacy of M3R inhibitors on tumor volume.

Results

The Autocrine Loop and ChAT Expression

A primary finding of this study is the existence of an autocrine loop in gastric cancer. Gastric cancer cells were found to express ChAT, enabling them to synthesize and release ACh independently of the nervous system.

Western blot analysis of ChAT expression in gastric cancer cell lines.

Immunohistochemical analysis further confirmed the presence and localization of ChAT within these cells, supporting the hypothesis of endogenous ACh production.

Immunohistochemical staining of ChAT in BGC823 cells.

M3R-EGFR Transactivation

The study demonstrated that ACh promotes proliferation specifically through the M3 muscarinic receptor (M3R). Activation of M3R leads to the "transactivation" of the Epidermal Growth Factor Receptor (EGFR) signaling pathway, subsequently triggering the phosphorylation of ERK1/2 and AKT—key drivers of cell survival and growth.

Therapeutic Potential and Chemosensitization

In vivo experiments showed that M3R antagonists like 4-DAMP significantly reduced tumor volumes (by approximately 70% in MKN45 models). Furthermore, blocking M3R enhanced the efficacy of the chemotherapy drug 5-Fluorouracil (5-Fu), reducing cell viability to 30-35% when used in combination.

Discussion

This research identifies a self-sustaining growth mechanism in gastric cancer driven by autocrine ACh. By acting through M3R to activate EGFR signaling, ACh facilitates tumor progression. While the precise molecular bridge for this transactivation in gastric cancer requires further elucidation, the findings suggest that targeting the M3R-EGFR axis—perhaps by repurposing existing clinical M3R antagonists—could offer a novel therapeutic strategy. Future studies should also explore the complex interplay between autocrine ACh and paracrine ACh from gastric nerves in vivo.

Summary updated

Abstract

Acetylcholine (ACh), known as a neurotransmitter, regulates the functions of numerous fundamental central and peripheral nervous system. Recently, emerging evidences indicate that ACh also plays an important role in tumorigenesis. However, little is known about the role of ACh in gastric cancer. Here, we reported that ACh could be auto-synthesized and released from MKN45 and BGC823 gastric cancer cells. Exogenous ACh promoted cell proliferation in a does-dependent manner. The M3R antagonist 4-DAMP, but not M1R antagonist trihexyphenidyl and M2/4 R antagonist AFDX-116, could reverse the ACh-induced cell proliferation. Moreover, ACh, via M3R, activated the EGFR signaling to induce the phosphorylation of ERK1/2 and AKT, and blocking EGFR pathway by specific inhibitor AG1478 suppressed the ACh induced cell proliferation. Furthermore, the M3R antagonist 4-DAMP and darifenacin could markedly inhibit gastric tumor formation in vivo. 4-DAMP could also significantly enhance the cytotoxic activity of 5-Fu against the MKN45 and BGC823 cells, and induce the expression of apoptosis-related proteins such as Bax and Caspase-3. Together, these findings indicated that the autocrine ACh could act through M3R and the EGFR signaling to promote gastric cancer cells proliferation, targeting M3R or EGFR may provide us a potential therapeutic strategy for gastric cancer treatment.
BibTeX
@inproceedings{yu2017acetylcholine,
  author = {Huangfei Yu and Hongwei Xia and Qiulin Tang and Huanji Xu and Guoqing Wei and Ying Chen and Xinyu Dai and Qiyong Gong and Feng Bi},
  title = {{Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation}},
  booktitle = {Scientific},
  year = {2017},
  doi = {10.1038/srep40802},
}
Figure